New obesity pill effective; safety issues under review

Article

The first potential new prescription weight-loss pill to reach the US market in more than a decade is effective and well tolerated, according to a manufacturer's new drug application, but potential safety issues have stalled its approval by the FDA.

The first potential new prescription weight-loss pill to reach the US market in more than a decade is effective and well tolerated, according to the manufacturer's new drug application (NDA), but potential safety issues have stalled its approval by FDA.

The investigational drug Qnexa (tesofensine) is a controlled-release, once-daily pill that combines low-dose, immediate-release phentermine with a controlled-release formulation of the antiseizure drug topiramate.

If it is approved, the drug would be recommended for obese patients (body mass index [BMI] ≥30kg/m2) or overweight patients (BMI ≥27 kg/m2) with weight-related comorbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity). It is intended to be used as a component of a diet and exercise program for weight loss and maintenance.

Additional reported risks include kidney stones, hyperammonemia (with or without encephalopathy, oligohydrosis, and hyperthermia), and visual disturbances.

Vivus, the drug's manufacturer, has announced plans to work with the FDA's Endocrinologic and Metabolic Drug Advisory Committee to resolve safety and labeling concerns in anticipation of the agency's scheduled October 28 decision on whether to approve the product.

Vivus Inc. VI-0521 (Qnexa) Advisory Committee Briefing Document. NDA 022580. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. July 15, 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/UCM218821.pdf. Accessed August 19, 2010.

Recent Videos
Revi System shows efficacy against urgency urinary incontinence | Image Credit: ics.org.
1 expert is featured in this series.
Researchers highlight risks of breastfeeding while taking Levetiracetam | Image Credit: uwaterloo.ca.
Ipek Ensari, PhD, highlights improved mental health in chronic pelvic pain from physical activity | Image Credit: scholars.mssm.edu
New pSNM system empowers patients in urge urinary incontinence treatment | Image Credit: trinityhealthmichigan.org.
Jannah Thompson, MD, highlights battery free device for UUI management | Image Credit: trinityhealthmichigan.org
Anietie Aliu, PhD, highlights racial barriers to breast cancer screening | Image Credit: bbc.com.
Anietie Aliu, PhD, discusses how to improve breast cancer screening disparities | Image Credit: bbc.com
Jennifer Payne, MD, highlights how to help young women with perimenopause symptoms | Image Credit: uvahealth.com/findadoctor.
Perimenopausal symptoms in young women discussed by Jennifer Payne, MD | Image Credit: uvahealth.com/findadoctor.
Related Content
© 2025 MJH Life Sciences

All rights reserved.